Nucleic acid tests for the detection of alpha human papillomaviruses

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Poljak, Mario ^a   Cuzick, Jack ^b   Kocjan, Boštjan J ^a   Iftner, Thomas ^c   Dillner, Joakim ^d   Arbyn, Marc ^e  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Cervical cancer; HPV; Screening; Test

Indexed keywords

MESSENGER RNA; NUCLEIC ACID;

AUTOMATION; CAPILLARY ELECTROPHORESIS; CHINA; COLPOSCOPY; CROSS-SECTIONAL STUDY; DNA EXTRACTION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IN SITU HYBRIDIZATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MULTICENTER STUDY (TOPIC); NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; PEER REVIEW; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WORLD HEALTH ORGANIZATION;

EID: 84875224393     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.105     Document Type: Review

References (63)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70-9.
2. Molijn A, Kleter B, Quint W, van Doorn LJ. Molecular diagnosis of human papillomavirus (HPV) infections. J Clin Virol 2005;32(Suppl. 1):S43-51.
3. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis Markers 2007;23:273-81.
4. Coutlee F, Mayrand MH, Roger M, Franco EL. Detection and typing of human papillomavirus nucleic acids in biological fluids. Public Health Genomics 2009;12:308-18.
5. Cox JT. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results. J Clin Virol 2009;45(Suppl. 1):S3-12.
6. Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 2010;118:520-8.
7. Witonsky J. Infectious disease molecular diagnostics: market review and opportunities. Genetic Engineering Biotechnology News 2011;31:14.
8. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
9. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol 2010;171:155-63.
10. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens - Part B: biological agents. Lancet Oncol 2009;10:321-2.
11. Iftner T, Villa LL. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr 2003;31:80-8.
12. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005;32(Suppl. 1):S34-42.
13. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24(Suppl. 3):S78-89.
14. Arbyn M, Dillner J, Schenck U, Nieminen P, Weiderpass E, Da Silva D, et al. 3. Methods for screening and diagnosis. In: Arbyn M, Anttila A, Jordan J, et al., editors. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd edition Luxembourg: Office for Official Publications of the European Communities; 2008. p. 69-152.
15. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26(Suppl. 10):K29-41.
16. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
17. Poljak M, Kocjan BJ. Commercially available tests for multiplex detection of alpha human papillomaviruses. Exp Rev Anti Infect Ther 2010;8:1139-62.
18. Cuschieri K. Human papillomavirus testing: the challenges of picking the right tools for the job. Exp Rev Obstet Gynecol 2011;6:643-53.
19. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119:1095-101.
20. Arbyn M, Ronco G, Anttila A, Meijer CJLM, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30(S5):F88-99.
21. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, et al. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010;118:116-22.
22. Belinson JL, Wu R, Belinson SE, Qu X, Yang B, Du H, et al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. Am J Clin Pathol 2011;135:790-5.
23. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-36.
24. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005;97:1072-9.
25. Stoler MH, Wright Jr TC, Sharma A, Apple R, Gutekunst K, Wright TL, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) HPV Study Group. Highrisk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011;135:468-75.
26. Castle PE, Stoler MH, Wright Jr TC, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011;12: 880-90.
27. Wright Jr TC, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL, ATHENA (Addressing THE Need for Advanced HPV Diagnostics) Study Group. Evaluation of HPV16 and HPV18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol 2011;136:578-86.
28. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011;49:3983-5.
29. Cuzick J, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J Med Virol 2010;82:1186-91.
30. Huang S, Erickson B, Tang N, Mak WB, Salituro J, Robinson J, et al. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology. J Clin Virol 2009;45(Suppl. 1):S19-23.
31. Poljak M, Ostrbenk A, Seme K, Ucakar V, Hillemanns P, Bokal EV, et al. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening. J Clin Microbiol 2011;49:1721-9.
32. Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi Rossi P, et al. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 test in a screening setting. J Clin Microbiol 2011;49:1446-51.
33. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008;26(Suppl. 10):K42-52.
34. Schutzbank TE, Ginocchio CC. Assessment of clinical and analytical performance characteristics of an HPV genotyping test. Diagn Cytopathol 2012;40:367-73.
35. Arbyn M, Schneider A, Gissmann, Kaufmann AM. Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 2: Applied clinical science. Future Virol 2012;7:19-24.
36. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, et al. Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunotest in populationbased cervical screening. J Clin Microbiol 2010;48:797-801.
37. Schmitt M, Dondog B, Waterboer T, Pawlita M, Tommasino M, Gheit T. Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping test. J Clin Microbiol 2010;48:143-9.
38. Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 2008;17:2536-45.
39. Burger EA, Kornor H, Klemp M, Lauvrak V, Kristiansen IS. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011;120:430-8.
40. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC. Efficiency of the APTIMA HPV Test for detection of HPV RNA and DNA targets. J Clin Virol 2009;45(Suppl. 1):S49-54.
41. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer 2011;129:691-701.
42. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Smith JS. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study). Gynecol Oncol 2012; [Epub ahead of print].
43. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. APTIMA HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Test but more specific at detecting cervical precancer and cancer. J Clin Microbiol 2011;49: 557-64.
44. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 2008;17:3033-42.
45. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C. Clinical performance of the APTIMA HPV Test for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 2009;45(Suppl. 1):S55-61.
46. Boulet GA, Micalessi IM, Horvath CA, Benoy IH, Depuydt CE, Bogers JJ. Nucleic acid-sequence based amplification test for HPV mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol 2010;48:2524-9.
47. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, Skomedal H, et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. Br J Cancer 2010;102:957-65.
48. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, et al. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA test in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 2010;48:2779-85.
49. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA test as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011;49:2643-50.
50. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. Triage of women with low-grade cervical lesions - HPV mRNA testing versus repeat cytology. PLoS One 2011;6:e24083.
51. Sorbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES. HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 2011;6:e26022.
52. Poljak M, Seme K, Gale N. Detection of human papillomaviruses in tissue specimens. Adv Anatomic Pathol 1998;5:216-34.
53. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009;125:2489-96.
54. Kitchener HC, Blanks R, Dunn G, Gunn L, Desai M, Albrow R, et al. Automationassisted versus manual reading of cervical cytology (MAVARIC): a randomised controlled trial. Lancet Oncol 2011;12:56-64.
55. Kinney W, Stoler MH, Castle PE. Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol 2010;134:193-9.
56. Stoler MH, Castle PE, Solomon D, Schiffman M. American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated tests. Am J Clin Pathol 2007;127:335-7.
57. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 2009;125:2151-8.
58. Wilkinson DE, Baylis SA, Padley D, Heath AB, Ferguson M, Pagliusi SR, et al. Establishment of the 1st World Health Organization international standards for human papillomavirus type 16 DNA and type 18 DNA. Int J Cancer 2010;126:2969-83.
59. Eklund C, Zhou T, Dillner J. WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010;48:4147-55.
60. Tabrizi SN. Quality assessment for human papillomavirus testing. Sex Health 2010;7:335-7.
61. Fagan EJ, Moore C, Jenkins C, Rossouw A, Cubie HA, James VL. External quality assessment for molecular detection of human papillomaviruses. J Clin Virol 2010;48:251-4.
62. Unger ER, Dillner J, editors. Human Papillomavirus Laboratory Manual. 1st Edition Geneva: World Health Organization; 2009. Available at: http://www.who.int/immunization/documents/en/(last accessed May 2012).
63. Cuzick J, Bergeron C, von Knebel Doeberitz M, Gravitt P, Jeronimo J, Lorincz AT, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012;30(S5):F107-16.